@article{18a7a90d30f046b496964d953e3e02d2,
title = "Sodium oxybate in the treatment of alcohol withdrawal syndrome: a randomized double-blind comparative study versus oxazepam. The GATE 1 trial",
abstract = "Benzodiazepines (BDZs) are the gold standard in the treatment of alcohol withdrawal syndrome (AWS). Sodium oxybate (SMO) has been tested as a treatment for AWS with encouraging results. The aim of this phase IV, multicenter, randomized, double-blind, double-dummy study was to evaluate the efficacy of SMO in comparison with oxazepam in the treatment of uncomplicated AWS.",
keywords = "alcohol withdrawal syndrome, sodium oxybate, alcohol withdrawal syndrome, sodium oxybate",
author = "Giovanni Addolorato and Fabio Caputo and Katrin Skala and Henriette Walter and Otto Lesch",
year = "2014",
doi = "10.1007/s40263-014-0183-1",
language = "English",
volume = "28",
pages = "743--752",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Limited:Private Bag 65901, Mairangi Bay, Auckland 1311 New Zealand:011 64 9 4770741, EMAIL: subs@adis.com, david.herrick@adis.co.nz, INTERNET: http://www.adis.com, Fax: 011 64 9 4770766",
}